

EXHIBIT A
Schedules 1-6 to Asset Purchase Agreement

SCHEDULE 1

CLINICAL TRIALS AND BUSINESS

Debtor is an allogeneic Gamma Delta T-cell therapy clinical stage company featuring novel, proprietary end-to-end bioinformatic, AI targeting, and manufacturing technologies to address solid tumors. Its end-to-end approach consists of target discovery and validation, product development, and on-site cGMP facilities, which we believe will allow us to leverage a new framework for the next generation of cell therapies.

From a development standpoint, it utilizes innovative non-engineered and engineered GDT technologies and is developing proprietary, virus-free cell engineering methods to develop novel therapies for solid tumors that it believe will be effective and cost-efficient. Deltacel™ (Deltacel) is its first allogeneic, off-the-shelf GDT cell-based product in Phase 1 clinical stage. Its Procel™ (“Procel”) and Isocel™ (“Isocel”) product candidates consist of allogeneic, engineered, off-the-shelf CAR-GDT cells, and they are currently in the preclinical development stage. Its Procel product candidate consists of engineered GDTs that target PD-L1. Its Isocel product candidate consists of engineered GDTs that target Mesothelin Isoform 2 positive tumors (“Iso-Meso”). Its Deltacel product candidate consists of non-engineered GDTs which it expands, enriches, and activates ex- vivo through a proprietary process, and it is intended to treat solid tumors regardless of the specific tumor antigen expression.

Debtor has a total of five clinical programs to study its key product candidates:

1. Deltacel-01: This phase 1 clinical trial is evaluating Deltacel in combination with low-dose targeted radiation for patients with non-small cell lung cancer (NSCLC).
2. Alexis-ISO-1: This phase 1 clinical trial is expected to evaluate Isocel in patients with Mesothelin Isoform 2 positive solid malignancies.
3. Alexis-PRO-1: This phase 1 clinical trial is expected to evaluate Procel in patients with PD-L1 positive solid malignancies.
4. Isocel combination: This phase 1 clinical trial is expected to evaluate Isocel in combination with low-dose radiation for patients with Mesothelin Isoform 2 positive solid malignancies.
5. Procel combination: This phase 1 clinical trial is expected to evaluate Procel in combination with low-dose radiation for patients with PD-L1 positive solid malignancies.

Buyer is purchasing all intellectual property, including but not limited to all patents, copyrights, trademarks and any goodwill in any marks, know how, trade secrets, trademarks, customer lists, product lists, data bases; all clinical data and records; domain names; and records and information related to the foregoing clinical trials or the business of Debtor, whether stored onsite or in another database, including but not limited to the attached.

TRADEMARK DISCLOSURE REPORT

MARK / TITLE	COUNTRY	STATUS	APPLICATION NUMBER	DATE FILED	REGISTRATION NUMBER	REGISTRATION DATE
ALEXIS-ISO-1	United States of America	Abandoned	97/126,855	Nov 16, 2021		
ALEXIS-PRO-1	United States of America	Abandoned	97/120,489	Nov 11, 2021		
BLADE-SMART	United States of America	Abandoned	87191715	Oct 3, 2016		
BRIGHTSPRING	United States of America	Abandoned	88727418	Dec 14, 2019		
CHPD1-GDT	United States of America	Abandoned	97/127,015	Nov 16, 2021		
DELTA CEL	United States of America	Allowed	97/444,141	Jun 6, 2022		
DIAMOND AI	United States of America	Registered	90265700	Oct 20, 2020	6410921	Jul 6, 2021
DIAMOND AI ARTIFICIAL INTELLIGENCE NEURAL NETWORK & DESIGN	United States of America	Abandoned	97/145,994	Nov 29, 2021		
DIAMOND ARTIFICIAL INTELLIGENCE (DAI)	United States of America	Abandoned	88336671	Mar 12, 2019		
EPITCR	United States of America	Abandoned	87770341	Jan 25, 2018		
EPITOPTCR	United States of America	Abandoned	87770254	Jan 25, 2018		
GAMMACEL	United States of America	Abandoned	97/194,538	Dec 29, 2021		

0000001

GREENPLANET PHARMA.	United States of America	Abandoned	88156752	Oct 16, 2018		
ICAR-ISO-GDT	United States of America	Abandoned	97/129,232	Nov 17, 2021		
ISOCEL	United States of America	Abandoned	97/145,914	Nov 29, 2021		
ISOCEL	United States of America	Abandoned	97/484,087	Jun 30, 2022		
KEY TO CANCER'S CURE	United States of America	Lapsed	86033393	Aug 9, 2013	5073577	Nov 1, 2016
KIROMIC	United States of America	Abandoned	97/484,071	Jun 30, 2022		
KIROMIC	United States of America	Lapsed	86033737	Aug 9, 2013	5073579	Nov 1, 2016
KIROMIC	United States of America	Registered	90264426	Oct 19, 2020	6410841	Jul 6, 2021
KIROMIC & Sun Design	United States of America	Allowed	97/484,081	Jun 30, 2022		
KIROMIC & Sun Design	United States of America	Registered	90264447	Oct 19, 2020	6410847	Jul 6, 2021
KIROTOPES	United States of America	Abandoned	87769734	Jan 25, 2018		
MAKING CANCER EXIT	United States of America	Abandoned	98/325,991	Dec 21, 2023		
MISCELLANEOUS DESIGN	United States of America	Abandoned	97/110,809	Nov 5, 2021		
NEOMUTAEPTOPES	United States of America	Abandoned	87769923	Jan 25, 2018		
PROCEL	United States of America	Abandoned	97/141,500	Nov 24, 2021		
PROCEL	United States of America	Abandoned	97/484,095	Jun 30, 2022		

0000002

SOOTHING SPRING	United States of America	Abandoned	88727158	Dec 13, 2019		
TESLA CAR-T	United States of America	Abandoned	97/110,989	Nov 5, 2021		
THE TESLA OF CAR-T	United States of America	Abandoned	97/110,937	Nov 5, 2021		
THE TESLA OF IMMUNOTHERAPY	United States of America	Abandoned	97/106,801	Nov 3, 2021		
WHERE AI & DATA MINING MEETS CANCER IMMUNOTHERAPY	United States of America	Abandoned	97/106,294	Nov 3, 2021		

0000003

OWNED PATENT DISCLOSURE REPORT

APPLICATION NUMBER	DATE FILED	COUNTRY	STATUS	PUBLICATION NUMBER	PUBLICATION DATE	PATENT NUMBER	GRANT DATE		
PCT/US2020/035183	May 29, 2020	PCT	Expired	WO/2020/243469	Dec 3, 2020			Methods for identifying and using disease-associate	https://patentimages.storage.googleapis.com/c/d/3/36/57/b603bb8f0cb6/wo2020243469a1.pdf
20760613.8	May 29, 2020	European Patent Office	Published	3977460	Apr 6, 2022			Methods for identifying and using disease-associate	https://worldwide.espacenet.com/patent/search?q=pn%3DEP3977460A1
17/613,191	May 29, 2020	United States of America	Published	2022-0310200	Sep 29, 2022			Methods for identifying and using disease-associate	https://worldwide.espacenet.com/patent/search?q=pn%3DUS2022310200A1
62/921,127	May 31, 2019	United States of America	Expired					Methods for identifying and using disease-associate	https://pubs.uspto.gov/dsearch-public/print/downloadBasicPdf/20220310200?requestToken=eyJzZWllOjIhYVVOQ1MtX0SOZMDQXLTQ2YzEyYmU5MmVlMmZlbnY2Y2Y2eDZlClJ2XlI0Ij42IR2YmEXZC1KNIMOLTO1NMEYmEOMSO3MmESN2I0ZmM3MzZlClleHAIOIB9
PCT/US2021/040348	Jul 2, 2021	PCT	Expired	WO 2022/010798	Jan 13, 2022			CONTAINING THE MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS	https://pubs.uspto.gov/dsearch-public/print/downloadBasicPdf/20240279353?requestToken=eyJzZWllOjIhYVVOQ1MtX0SOZMDQXLTQ2YzEyYmU5MmVlMmZlbnY2Y2Y2eDZlClJ2XlI0Ij42IR2YmEXZC1KNIMOLTO1NMEYmEOMSO3MmESN2I0ZmM3MzZlClleHAIOIB9
21755850.1	Jul 2, 2021	European Patent Office	Published	4175650	May 10, 2023			CONTAINING THE MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS	https://worldwide.espacenet.com/patent/search?q=pn%3DEP4175650A1
18/004,158	Jul 2, 2021	United States of America	Published	2024-0279353	Aug 22, 2024			CONTAINING THE MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS	https://worldwide.espacenet.com/patent/search?q=pn%3DUS2024279353A1

0000001

63/048,488	Jul 6, 2020	United States of America	Expired				MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS	https://pubs.uspto.gov/directsearch-public/print/downloadBasicPdf/20240279353?requestToken=eyJzdWVlbnVwQjI1MTcxOjUyZmMzMDQxLTQyZTEyZWY1MzZBNmZlCjJ2XHU4ZTRkZmE4ZC1kNmM0LTQ1NTEyME0MS03MmE5N2l0ZmMzMzZElCjEHAIOB9
63/115,465	Nov 18, 2020	United States of America	Expired				MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS	https://pubs.uspto.gov/directsearch-public/print/downloadBasicPdf/20240279353?requestToken=eyJzdWVlbnVwQjI1MTcxOjUyZmMzMDQxLTQyZTEyZWY1MzZBNmZlCjJ2XHU4ZTRkZmE4ZC1kNmM0LTQ1NTEyME0MS03MmE5N2l0ZmMzMzZElCjEHAIOB9
63/185,790	May 7, 2021	United States of America	Expired				MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS	https://pubs.uspto.gov/directsearch-public/print/downloadBasicPdf/20240279354?requestToken=eyJzdWVlbnVwQjI1MTcxOjUyZmMzMDQxLTQyZTEyZWY1MzZBNmZlCjJ2XHU4ZTRkZmE4ZC1kNmM0LTQ1NTEyME0MS03MmE5N2l0ZmMzMzZElCjEHAIOB9
63/243,524	Sep 13, 2021	United States of America	Expired				MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS	https://pubs.uspto.gov/directsearch-public/print/downloadBasicPdf/20240279354?requestToken=eyJzdWVlbnVwQjI1MTcxOjUyZmMzMDQxLTQyZTEyZWY1MzZBNmZlCjJ2XHU4ZTRkZmE4ZC1kNmM0LTQ1NTEyME0MS03MmE5N2l0ZmMzMzZElCjEHAIOB9
PCT/US2021/040365	Jul 2, 2021	PCT	Expired	WO 2022/108627	May 27, 2022		CONTAINING THE GAMMA-DELTA T CELL MANUFACTURING PROCESSES AND CHIMERIC PD1 RECEPTOR MOLECULES Gamma-delta t cell manufacturing processes and chimeric pd1	https://worldwide.espacenet.com/patent/search?q=pn%3DWO2022108627A1
3,202,233	Jul 2, 2021	Canada	Pending					https://patents.google.com/patent/CA3202233A1/en?q=3,202,233

PCT/US2021/059652	Nov 17, 2021	PCT	Expired						MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS	https://pubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/20240293544?requestToken=eyJzdWllOiJhbnV0MTcxOS02MDQxLTQ2YTZlbnV5MjI0MjIyZTg0ZC1jZ2xiOjI4ZTR2YmEzZC1kNmM0LTQ1NjE0MjI0ZmM5NSN2I0ZmM3MzZlClleHAiOiB9meIyMjE0MjI0ZmM5NSN2I0ZmM3MzZlClleHAiOiB9
21939966.4	Nov 17, 2021	European Patent Office	Published	4333983	Mar 13, 2024				CONTAINING THE MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS	https://worldwide.espacenet.com/patent/search?q=pn%3DEP4333983A1
62024096321.0	Nov 17, 2021	Hong Kong	Published	40107531	Oct 18, 2024				CONTAINING THE MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS	https://worldwide.espacenet.com/patent/search?q=pn%3DEP4248368A4
18/558,701	Nov 17, 2021	United States of America	Published	2024-0293544	Sep 5, 2024				CONTAINING THE MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS	https://worldwide.espacenet.com/patent/search?q=pn%3DUS024293544A1
PCT/US2021/058436	Nov 8, 2021	PCT	Expired						DISEASE-ASSOCIATED ISOFORM IDENTIFIER	https://worldwide.espacenet.com/patent/search?q=pn%3DEP4248368A1
21895359.4	Nov 8, 2021	European Patent Office	Published	4248368	Sep 27, 2023				DISEASE-ASSOCIATED ISOFORM IDENTIFIER	https://worldwide.espacenet.com/patent/search?q=pn%3DUS023420077A1
18/037,756	Nov 8, 2021	United States of America	Published	2023-0420077	Dec 28, 2023				DISEASE-ASSOCIATED ISOFORM IDENTIFIER	https://pubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/20230420077?requestToken=eyJzdWllOiJhbnV0MTcxOS02MDQxLTQ2YTZlbnV5MjI0MjIyZTg0ZC1jZ2xiOjI4ZTR2YmEzZC1kNmM0LTQ1NjE0MjI0ZmM5NSN2I0ZmM3MzZlClleHAiOiB9meIyMjE0MjI0ZmM5NSN2I0ZmM3MzZlClleHAiOiB9
63/115,356	Nov 18, 2020	United States of America	Expired						PEPTIDE COMPOSITIONS FOR THE TREATMENT OF PATHOGENIC	https://worldwide.espacenet.com/patent/search?family/076250433/publication/WO2021226520A1?q=WO2021226520
PCT/US2021/031387	May 7, 2021	PCT	Expired	WO 2021/226520	Nov 11, 2021					

0000003

63/101,640	May 8, 2020	United States of America	Expired					Could not verify - not in public database	
63/094,528	Oct 21, 2020	United States of America	Expired					Could not verify - not in public database	
21180389.5	Nov 19, 2015	European Patent Office	Abandoned	3903787	Nov 3, 2021			NANOPARTICLE-BASED VACCINE TARGETING CANCER/TESTIS ANTIGENS (CTA) AND ITS USE IN SOLID AND HEMATOLOGICAL MALIGNANCIES	https://worldwide.espacenet.com/patent/search?q=pn%3DEP3903787A1
15861304.2	Nov 19, 2015	Belgium	Issued	3220913			Sep 8, 2021	NANOPARTICLE-BASED VACCINE TARGETING CANCER/TESTIS ANTIGENS (CTA) AND ITS USE IN SOLID AND HEMATOLOGICAL MALIGNANCIES	https://worldwide.espacenet.com/patent/search?q=pn%3DEP3220913A1
15861304.2	Nov 19, 2015	Switzerland	Issued	3220913			Sep 8, 2021	NANOPARTICLE-BASED VACCINE TARGETING CANCER/TESTIS ANTIGENS (CTA) AND ITS USE IN SOLID AND HEMATOLOGICAL MALIGNANCIES	https://worldwide.espacenet.com/patent/search?q=pn%3DEP3220913A1
15861304.2	Nov 19, 2015	Germany	Issued	3220913			Sep 8, 2021	NANOPARTICLE-BASED VACCINE TARGETING CANCER/TESTIS ANTIGENS (CTA) AND ITS USE IN SOLID AND HEMATOLOGICAL MALIGNANCIES	https://worldwide.espacenet.com/patent/search?q=pn%3DEP3220913A1

0000004

15861304.2	Nov 19, 2015	Denmark	Abandoned	3220913		3220913	Sep 8, 2021	NOVEL NANOPARTICLE-B ASED VACCINE TARGETING CANCER/TESTIS ANTIGENS (CTA) AND ITS USE IN SOLID AND HEMATOLOGICAL MALIGNANCIES	https://worldwide.espacenet.com/patent/search?q=pn%3DEP3220913A1
15861304.2	Nov 19, 2015	European Patent Office	Issued	3220913	Sep 27, 2017	3220913	Sep 8, 2021	NOVEL NANOPARTICLE-B ASED VACCINE TARGETING CANCER/TESTIS ANTIGENS (CTA) AND ITS USE IN SOLID AND HEMATOLOGICAL MALIGNANCIES	https://worldwide.espacenet.com/patent/search?q=pn%3DEP3220913A1
15861304.2	Nov 19, 2015	France	Abandoned	3220913		3220913	Sep 8, 2021	NOVEL NANOPARTICLE-B ASED VACCINE TARGETING CANCER/TESTIS ANTIGENS (CTA) AND ITS USE IN SOLID AND HEMATOLOGICAL MALIGNANCIES	https://worldwide.espacenet.com/patent/search?q=pn%3DEP3220913A1
15861304.2	Nov 19, 2015	United Kingdom	Issued	3220913		3220913	Sep 8, 2021	NOVEL NANOPARTICLE-B ASED VACCINE TARGETING CANCER/TESTIS ANTIGENS (CTA) AND ITS USE IN SOLID AND HEMATOLOGICAL MALIGNANCIES	https://worldwide.espacenet.com/patent/search?q=pn%3DEP3220913A1
15861304.2	Nov 19, 2015	Ireland	Issued	3220913		3220913	Sep 8, 2021	NOVEL NANOPARTICLE-B ASED VACCINE TARGETING CANCER/TESTIS ANTIGENS (CTA) AND ITS USE IN SOLID AND HEMATOLOGICAL MALIGNANCIES	https://worldwide.espacenet.com/patent/search?q=pn%3DEP3220913A1

0000005

15861304.2	Nov 19, 2015	Italy	Issued	3220913		3220913	Sep 8, 2021	NOVEL NANOPARTICLE-B ASED VACCINE TARGETING CANCER/TESTIS ANTIGENS (CTA) AND ITS USE IN SOLID AND HEMATOLOGICAL MALIGNANCIES	https://worldwide.espacenet.com/patent/search?q=pn%3DEP3220913A1
15861304.2	Nov 19, 2015	Monaco	Issued	3220913		3220913	Sep 8, 2021	NOVEL NANOPARTICLE-B ASED VACCINE TARGETING CANCER/TESTIS ANTIGENS (CTA) AND ITS USE IN SOLID AND HEMATOLOGICAL MALIGNANCIES	https://worldwide.espacenet.com/patent/search?q=pn%3DEP3220913A1
PCT/US2017/022168	Mar 13, 2017	PCT	Expired	WO/2017/160761	Sep 21, 2017			Compositions and methods for treating cancers	https://pubs.uspto.gov/direct-search-public/print/downloadBasicPdf/10717774?requesttoken=evjzdwilou1hvw01mck050zmdqxltozyetvmu5wv1lm2bmzt1y27ad2gic12zxliou4zt1k2ymfexzc1knjmol1q1nmfeyme0ms03mme5n2i0zmm3mzeilclieha0ib9
201780017624.6	Mar 13, 2017	China	Abandoned	109310738	Feb 5, 2019			Compositions and methods for treating cancers	https://worldwide.espacenet.com/patent/search?q=pn%3DCN109310738A
17767289.6	Mar 13, 2017	European Patent Office	Abandoned	3429613	Jan 23, 2019			Compositions and methods for treating cancers	https://worldwide.espacenet.com/patent/search?q=pn%3DEP3429613A2
MX/a/2018/011046	Mar 13, 2017	Mexico	Abandoned					Could not verify - not in public database	Likely same as above
16/082,363	Mar 13, 2017	United States of America	Expired	2019-0031732	Jan 31, 2019	10,717,774	Jul 21, 2020	Compositions and methods for treating cancers	https://worldwide.espacenet.com/patent/search?q=pn%3DUS2019031732A1
PCT/US2023/068753	Jun 20, 2023	PCT	Expired	WO 2023/250336	Dec 28, 2023			METHODS FOR GENERATING GAMMA DELTA T-CELLS AND RELATED	https://worldwide.espacenet.com/patent/search?q=pn%3DWO2023250336A1
23827993.9	Jun 20, 2023	European Patent Office	Pending					Could not verify - not in public database	
18/876,630	Jun 20, 2023	United States of America	Pending					Could not verify - not in public database	

0000006

63/354,027	Jun 21, 2022	United States of America	Expired							Could not verify - not in public database	
63/354,045	Jun 21, 2022	United States of America	Expired							Could not verify - not in public database	
63/389,308	Jul 14, 2022	United States of America	Abandoned							Could not verify - not in public database	

SCHEDULE 2
PARTIAL LIST OF INVENTORY AND EQUIPMENT

C926 S2-T0225-WEM Doc S2-T E||6q 04\T0\52 b9d6 T3 04 33

ASSET DISCLOSURE REPORT

Date Acq	Date Sold	Description	Meth/Life	Cost	Net Book Val
Asset A/C#: 15014 - LHI - R&D					
12/1/2019		Laboratory renovation	SLP / 1.417	19,231.67	0.00
9/1/2020		Vivarium	SLP / 5.667	410,062.05	156,788.44
9/1/2020		GMP	SLP / 5.667	409,435.67	156,548.94
12/1/2020		Stainless Steel Piping	SLP / 5.417	52,501.25	21,000.50
1/1/2021		GMP Improvements	SLP / 5.333	14,610.31	5,935.43
1/1/2021		GMP Improvements	SLP / 5.333	30,326.00	12,319.94
6/1/2021		GMP Improvements	SLP / 5.167	10,000.00	4,677.42
8/1/2021		GMP air exchanges	SLP / 5	56,344.12	27,232.99
9/1/2021		ISO 8 Ante Clean Room for GMP CR	SLP / 5	44,382.50	22,191.25
2/1/2022		GMP Quality Control Lab	SLP / 4.25	452,052.00	230,457.87
3/1/2022		GMP1/Cold/Ware Finish	SLP / 4.167	1,699,830.90	883,912.06
4/1/2022		GMP1	SLP / 4.083	533,154.83	282,898.48
4/1/2022		Laboratory sink at Suite 140	SLP / 4.083	13,256.30	7,033.95
6/1/2022		GMP1.1	SLP / 3.917	1,054,140.25	583,141.41
6/1/2022		Cleanroom	SLP / 3.917	1,896,890.86	1,049,343.88
6/1/2022		Suite 255	SLP / 3.917	72,182.53	39,930.76
9/1/2022		R410A 2-Ton Run Tru AC	SLP / 3.667	7,500.00	4,431.83
8/1/2023		Circuit 1 Compressors (2)	SLP / 1.75	38,700.81	25,800.53
8/1/2023		Emon Meter - Suites 144, 290 & 291	SLP / 1.75	8,298.23	5,532.16
8/1/2023		Emon Meter - Suite 200	SLP / 1.75	5,071.30	3,380.87
Asset A/C# totals: 15014 - LHI - R&D (20 assets)				6,827,971.58	3,522,558.71

Asset A/C#: 15016 - LHI - G&A					
3/1/2016		Leasehold improvements	SLP / 7	259,703.97	0.00
3/1/2017		Generator system	SLP / 2.5	22,889.66	0.00
10/1/2019		Electrical upgrade	SLP / 1.583	5,234.98	0.00
12/1/2020		Offices	SLP / 5.417	50,594.57	20,237.82
7/1/2021		Leasehold improvements	SLP / 5	7,536.45	3,517.01
9/1/2021		Camera system	SLP / 5	10,459.12	5,229.56
12/1/2021		Security system 1	SLP / 4.417	22,107.80	10,845.33
12/1/2021		Security system 2	SLP / 4.417	19,988.49	9,805.67
12/1/2021		Various improvements	SLP / 4.417	19,283.66	9,459.92
12/1/2022		Access control system	SLP / 3.417	104,825.31	66,474.58
11/1/2023		Security system	SLP / 2.5	21,587.50	18,709.17
Asset A/C# totals: 15016 - LHI - G&A (11 assets)				544,211.51	144,279.06

Asset A/C#: 15024 - Laboratory Equipment - R&D			
10/31/2013	Laboratory Equipment	SLP / 3	8,435.70
12/4/2013	Laboratory Equipment	SLP / 3	8,750.00
12/31/2013	Laboratory Equipment	SLP / 3	5,500.00
4/30/2014	Laboratory Equipment	SLP / 3	6,792.48
6/30/2014	Laboratory Equipment	SLP / 3	17,911.62
12/31/2014	Laboratory Equipment	SLP / 3	10,294.00
3/31/2015	Laboratory Equipment	SLP / 3	19,350.00
9/30/2015	Laboratory Equipment	SLP / 3	7,530.00
12/9/2015	Laboratory Equipment	SLP / 3	12,665.25
4/1/2016	Laboratory Equipment	SLP / 3	5,298.84
4/1/2016	Laboratory Equipment	SLP / 3	5,298.84
7/1/2016	Laboratory Equipment	SLP / 3	36,467.72
8/1/2016	Laboratory Equipment	SLP / 3	6,824.85
11/1/2019	Freezer TSX ULT 600-box A-V & sliding drawer	SLP / 7	14,104.77
11/1/2019	Cellometer K2 SK-150	SLP / 7	14,180.00
11/1/2019	Spectrophotometer, Nonodrop One	SLP / 7	7,839.47
12/1/2019	NovoCyt 3000 and NovoSampler Pro	SLP / 7	100,935.98
12/1/2019	Option Infinite M Plex	SLP / 7	20,265.14
12/1/2019	4D-Nucleofector X Unit FL1	SLP / 7	7,680.80
12/1/2019	4D-Nucleofector Core Unit FL1	SLP / 7	5,542.40
12/1/2019	Gbox Demo XX6 Kit 2	SLP / 7	27,129.00
1/1/2020	Leica DM IL LED Fluio	SLP / 7	18,507.40
2/1/2020	Incucyte S3 System Package	SLP / 7	114,630.23
2/1/2020	Insert Plate Carrier Smart 2 MBS 96 Spare	SLP / 7	12,355.68
3/1/2020	Heracell Vios 160i CO2 Incubator	SLP / 7	15,323.56
3/1/2020	QPCR Instrument Q 2-Channel F/DNA/RNA	SLP / 7	11,786.33
3/1/2020	Simpliamp Thermal Cycler	SLP / 7	5,198.25
7/1/2020	NC-3000 Fixed Assays Package	SLP / 7	30,040.00
9/1/2020	IVIS Spectrum	SLP / 7	157,297.72
9/1/2020	V3.5 Innorack	SLP / 7	15,149.00
11/1/2020	Sorvall Legent RT Refrigerated Benchtop Centrifuge	SLP / 7	5,985.00
12/1/2020	ULT FZ TSX60086A 115V/60HZ	SLP / 7	13,749.00
12/1/2020	Thermo Scientific ST40 Benchtop Centrifuge w/ TX-750 Rotor	SLP / 7	24,842.00
1/1/2021	AutoMACS Pro Separator	SLP / 7	50,375.00
1/1/2021	CliniMACS Plus Instrument	SLP / 7	103,040.00
1/1/2021	QuickPlex SQ 120MM Reader	SLP / 7	117,100.00
3/1/2021	Heracell Vios 160i CO2 Incubator	SLP / 7	12,991.65
3/1/2021	Heracell Vios 160i CO2 Incubator	SLP / 7	12,991.66

3/1/2021	TSX ULT 600-box A-Volt	SLP / 7	12,999.00	7,428.00
3/1/2021	Somnosuite Low Flow Vaporizer	SLP / 7	5,564.20	3,179.54
3/1/2021	Cellometer K2 Image Cytometer	SLP / 7	18,615.00	10,637.13
3/1/2021	Type A2 Bio Safety Cabinet	SLP / 7	9,475.00	5,414.28
3/1/2021	Cell Harvest Pump	SLP / 7	15,126.34	8,643.61
5/1/2021	NovoCyt 3005 Combo	SLP / 7	101,712.40	60,543.10
5/1/2021	IncuCyt S3 System Package	SLP / 7	120,979.35	72,011.52
5/1/2021	GMP Equipment	SLP / 7	147,190.36	87,613.31
6/1/2021	Hettich Rotanta 460R Refrigerated Centrifuge	SLP / 7	5,570.00	3,381.79
8/1/2021	CO2 Incubator Validation Svc w Temperature Map	SLP / 7	5,493.89	3,466.39
8/1/2021	CO2 Incubator Validation Svc w Temperature Map	SLP / 7	5,493.89	3,466.39
8/1/2021	CO2 Incubator Validation Svc w Temperature Map	SLP / 7	5,493.89	3,466.39
8/1/2021	CO2 Incubator Validation Svc w Temperature Map	SLP / 7	5,493.89	3,466.39
8/1/2021	Laboratory Freezer Validation Svc w Temperature Map	SLP / 7	5,494.00	3,466.44
8/1/2021	Laboratory Freezer Validation Svc w Temperature Map	SLP / 7	5,494.00	3,466.44
8/1/2021	Laboratory Freezer Validation Svc w Temperature Map	SLP / 7	5,494.00	3,466.44
8/1/2021	Ultra-low Temperature Freezers Validation Svc w Temperature SLP / 7	SLP / 7	6,144.00	3,876.58
8/1/2021	Ultra-low Temperature Freezers Validation Svc w Temperature SLP / 7	SLP / 7	6,144.00	3,876.58
8/1/2021	Cabinet Biosafety Stand	SLP / 7	10,237.42	6,459.33
9/1/2021	Cell Dyn Emerald	SLP / 7	11,202.60	7,201.68
12/1/2021	Evos XL Core Mechanical Stage	SLP / 7	6,691.73	4,540.83
1/1/2022	Cabinet Biosafety Stand	SLP / 7	12,810.00	8,845.00
2/1/2022	Cabinet Biosafety Stand	SLP / 7	11,071.30	7,776.28
2/1/2022	Taylor Wharton 10K Liquid Nitrogen Dewar SN562-010-p7	SLP / 7	5,600.00	3,933.33
2/1/2022	Thermo Fisher Scientific ULT21286-10-A44-80 Freezer SNO1	SLP / 7	7,100.00	4,986.91
2/1/2022	CO2 Shaking Incubator w Flat Mat Platform 120V	SLP / 7	8,440.47	5,928.43
3/1/2022	Mobile Compact5 Multi Patient Anesthesia Center	SLP / 7	13,679.22	9,770.87
4/1/2022	Evos XL Core Mechanical Stage	SLP / 7	6,640.00	4,821.90
4/1/2022	Evos XL Core Mechanical Stage	SLP / 7	6,640.00	4,821.90
4/1/2022	Evos XL Core Mechanical Stage	SLP / 7	6,640.00	4,821.90
4/1/2022	Evos XL Core Mechanical Stage	SLP / 7	6,640.00	4,821.90
5/1/2022	Invitrogen EVOS XL Core Configured Cell Imager with Mecha	SLP / 7	6,691.73	4,939.14
5/1/2022	Invitrogen EVOS XL Core Configured Cell Imager with Mecha	SLP / 7	6,640.00	4,900.95
5/1/2022	Heracell VIOS 160i CO2 Incubator Single Chamber	SLP / 7	8,634.00	6,372.70
5/1/2022	Heracell VIOS 160i CO2 Incubator Single Chamber	SLP / 7	8,634.00	6,372.70
5/1/2022	Heracell VIOS 160i CO2 Incubator Single Chamber	SLP / 7	8,634.00	6,372.70
5/1/2022	Heracell VIOS 160i CO2 Incubator Single Chamber	SLP / 7	8,635.77	6,374.02
5/1/2022	Cabinet Biosafety Stand A2 115V 10IN 3FT	SLP / 7	9,237.49	6,818.15
5/1/2022	Cabinet Biosafety Stand A2 115V 10IN 3FT	SLP / 7	9,237.49	6,818.15
5/1/2022	Heracell VIOS 160i CO2 Incubator Single Chamber CR SS	SLP / 7	14,296.14	10,551.91
5/1/2022	CelCulture Incubator 170L IR Sensor CO2 Control	SLP / 7	7,328.07	5,408.81

5/1/2022	CellCulture Incubator 170L IR Sensor CO2 Control	SLP / 7	7,328.07	5,408.81
6/1/2022	ThawSTAR Cryo Bags Automated Thawing System	SLP / 7	21,400.95	16,050.72
6/1/2022	PHCbI MPR Series 24.2 C Ft. Hinged Glass Door Refrigerator	SLP / 7	6,048.78	4,536.59
6/1/2022	T-seal Mobile Hand Unit	SLP / 7	7,553.45	5,665.10
6/1/2022	T-seal Mobile Hand Unit	SLP / 7	7,531.18	5,648.38
6/1/2022	SCDIIB Sterile Tube Welder RX	SLP / 7	23,770.50	17,827.88
6/1/2022	SCDIIB Sterile Tube Welder RX	SLP / 7	23,770.50	17,827.88
6/1/2022	Flake Ice Maker Modular Scots	SLP / 7	6,776.38	5,082.29
6/1/2022	Fisherbrand Bead Mill 24 Homogenizer	SLP / 7	6,250.13	4,687.59
6/1/2022	Rotanta 460 Benchtop Centrifuge	SLP / 7	11,392.50	8,544.37
6/1/2022	Rotanta 460 Benchtop Centrifuge	SLP / 7	11,392.50	8,544.37
6/1/2022	QStudio Fix96Wfast Inst LPTP 1 System	SLP / 7	32,128.13	24,096.10
6/1/2022	SuperMACS II Separator	SLP / 7	11,828.62	8,871.46
6/1/2022	Cellometer K2 Image Cytometer Laptop	SLP / 5	3,245.00	2,109.26
6/1/2022	Cellometer K2 Image Cytometer	SLP / 7	32,408.33	24,306.26
6/1/2022	Cellometer K2 Image Cytometer	SLP / 7	32,408.33	24,306.26
6/1/2022	Cellometer K2 Image Cytometer	SLP / 7	32,408.33	24,306.26
6/1/2022	Cellometer K2 Image Cytometer	SLP / 7	32,408.34	24,306.27
6/1/2022	Cellometer K2 Image Cytometer	SLP / 7	29,668.00	22,251.00
6/1/2022	Cellometer K2 Image Cytometer	SLP / 7	29,668.00	22,251.00
6/1/2022	Welder PVC TSCD ii F/Sterile Tubing	SLP / 7	20,906.44	15,679.83
6/1/2022	Measuring Equipment	SLP / 7	147,924.75	110,943.56
6/1/2022	GelLocket Stackable CO2 Incubators	SLP / 7	36,355.10	27,266.32
6/1/2022	GelLocket Stackable CO2 Incubators	SLP / 7	36,355.10	27,266.32
6/1/2022	GelLocket Stackable CO2 Incubators	SLP / 7	36,355.10	27,266.32
6/1/2022	GelLocket Stackable CO2 Incubators	SLP / 7	36,355.10	27,266.32
6/1/2022	GelLocket Stackable CO2 Incubators	SLP / 7	36,355.11	27,266.33
6/1/2022	GelLocket Stackable CO2 Incubators	SLP / 7	17,833.79	13,375.34
6/1/2022	GelLocket Stackable CO2 Incubators	SLP / 7	17,833.79	13,375.34
6/1/2022	Incubator Ref Touchscreen 33CF 115/60	SLP / 7	21,716.37	16,287.27
7/1/2022	PHCbI Laboratory Refrigerator 48.2 cu ft.	SLP / 7	8,363.42	6,372.14
7/1/2022	PHCbI MPR Series 24.2 C Ft. Hinged Glass Door Refrigerator	SLP / 7	5,998.78	4,570.51
7/1/2022	Panasonic 24.4 C Ft. Manual Defrost -30C Upright Freezer	SLP / 7	6,892.88	5,251.71
8/1/2022	Eppendorf™ Model 5430R Microcentrifuges	SLP / 7	7,926.40	6,133.53
8/1/2022	1300 Series Class II Type A2 Biological Safety Cabinet	SLP / 7	9,271.00	7,173.98
8/1/2022	Toshiba E3015AC Color MFP Printer	SLP / 5	6,702.03	4,579.72
9/1/2022	IRTD 400 Standard (M2801) System	SLP / 7	5,554.50	4,364.24
9/1/2022	Chart MVE 819P-190F-GB	SLP / 7	19,731.56	15,503.37
9/1/2022	Chart MVE 1536P-190AF-GB High Efficiency/Vapor Series	SLP / 7	25,925.75	20,370.23
9/1/2022	PHCbI MPR Series 24.2 C Ft. Hinged Glass Door Refrigerator	SLP / 7	5,901.53	4,636.90
9/1/2022	PHCbI MPR Series 24.2 C Ft. Hinged Glass Door Refrigerator	SLP / 7	5,901.53	4,636.90
9/1/2022	PHCbI MPR Series 24.2 C Ft. Hinged Glass Door Refrigerator	SLP / 7	5,901.53	4,636.90

9/1/2022	PHCbI MPR Series 24.2 C Ft. Hinged Glass Door Refrigerator	SLP / 7	5,901.53	4,636.90
9/1/2022	VIP Eco Upright Ultra Low Temperature Freezer w Natural Re	SLP / 7	17,158.83	13,481.94
9/1/2022	Panasonic MCO-801CL-PA CytoGrow	SLP / 7	16,398.64	12,884.65
9/1/2022	Panasonic MCO-801CL-PA CytoGrow	SLP / 7	16,398.63	12,884.64
9/1/2022	6 Fix96wfast Instltp 1 System	SLP / 7	36,067.01	28,338.36
9/1/2022	TSCD II Sterile Tube Welder	SLP / 7	23,304.58	18,310.73
9/1/2022	Instrument Infinite 200 Pro Option M Plex	SLP / 7	25,139.52	19,752.48
10/1/2022	Kaye Temperature Sensor	SLP / 7	83,803.00	66,842.86
10/1/2022	Geldoc Go Imaging System	SLP / 7	12,024.34	9,590.84
10/1/2022	Type A2 Biological Safety Cabinet 1300 Series Class II	SLP / 7	9,271.00	7,394.72
10/1/2022	Type A2 Biological Safety Cabinet 1300 Series Class II	SLP / 7	9,271.00	7,394.72
10/1/2022	Type A2 Biological Safety Cabinet 1300 Series Class II	SLP / 7	9,271.00	7,394.72
10/1/2022	Type A2 Biological Safety Cabinet 1300 Series Class II	SLP / 7	9,271.00	7,394.72
10/1/2022	Type A2 Biological Safety Cabinet 1300 Series Class II	SLP / 7	9,271.00	7,394.72
10/1/2022	Type A2 Biological Safety Cabinet 1300 Series Class II	SLP / 7	9,271.00	7,394.72
10/1/2022	CliniMACS Plus Instrument	SLP / 7	104,890.00	83,662.26
11/1/2022	CO2 Inc IR GelJacket 10CF 115V 60HZ	SLP / 7	12,623.90	10,219.36
11/1/2022	CO2 Inc IR GelJacket 10CF 115V 60HZ	SLP / 7	12,623.90	10,219.36
11/1/2022	CO2 Inc IR GelJacket 10CF 115V 60HZ	SLP / 7	12,623.90	10,219.36
12/1/2022	Freezer - Panasonic 24.4 CF Manual Defrost -30C Upright 11	SLP / 7	6,992.68	5,743.98
12/1/2022	Freezer - CryoMed w OPC UA General Purpose w Printer 1.7	SLP / 7	24,745.32	20,326.50
9/1/2023	LN2 Freezer - S-1500AB LN2 Storage System	SLP / 7	15,101.07	14,022.41
11/1/2023	PTS Nexgen Instrument Kit	SLP / 7	69,265.10	65,966.77
1/1/2024	PTS Nexgen Instrument Kit	SLP / 7	9,760.00	9,527.62
Asset A/C# totals: 15024 - Laboratory Equipment - R&D (142 assets)			3,135,990.08	1,948,786.48

Asset A/C# totals: 15036 - Office Fur, Fix & Equipment - G&A				
1/1/2018	Website upgrade	SLP / 5	10,110.00	0.00
7/1/2019	Dell Precision 7920 Tower	SLP / 5	6,492.45	432.83
2/1/2022	Fire Alarm System	SLP / 5	8,114.04	4,733.20
2/1/2022	Offsite Network System	SLP / 5	64,575.90	37,669.27
2/1/2022	Onsite Network System	SLP / 5	20,225.87	11,798.42
5/1/2022	1U Supermicro SuperServer	SLP / 5	13,880.00	8,790.67
5/1/2022	1U Supermicro SuperServer	SLP / 5	13,880.00	8,790.67
Asset A/C# totals: 15036 - Office Fur, Fix & Equipment - G&A (7 assets)			137,278.26	72,215.06

Asset A/C# totals: 15044 - Software - R&D				
10/1/2018	KAI Software	SLP / 5	121,505.45	0.00
2/1/2019	Cancer Specific Alt Splicing Software	SLP / 5	20,000.00	0.00

8/1/2020 Cancer Specific/Alt Splicing Software
8/1/2021 Incucyte Cell-by-Cell Software
8/1/2021 Bioinformatics Protein Research Software

SLP / 3
SLP / 3
SLP / 3

10,250.00 0.00
20,423.53 2,836.61
39,335.00 5,463.19
211,513.98 8,299.80

Asset A/C#: 15046 - Software - G&A

7/1/2021 P2P software SLP / 3
9/1/2021 P2P software enhancement SLP / 2,833
10/1/2021 P2P software enhancement SLP / 2,583
11/1/2021 P2P software enhancement SLP / 2,667

Asset A/C# totals: 15046 - Software - G&A (4 assets)

Grand Totals: (189 assets)

105,800.00 11,755.55
14,400.00 1,694.12
14,400.00 929.03
13,400.00 1,675.00
148,000.00 16,053.70
11,004,965.41 5,712,192.81

SCHEDULE 3
ASSIGNED CONTRACTS

To the extent that any assumed liability or obligation as set forth on Schedule 6 is determined to be an executory contract or unexpired lease, Buyer reserve its right to revise Schedule 3 to include such contract or lease.

Kironic Contracts (Clinical Operations and CT, CRO, sites, consultants)						
No.	Other Party	Agreement Subject	Category	Effective Date	Expiration Date	Proposed Cure
1	Dark Horse Consulting Group, Inc.	Consulting Agreement	Clinical Operations and CT, CRO, sites, consultants	3/18/2022	on the second anniversary of the Effective Date or if later, upon the completion of the Services in accordance with any pending Statement of Work	As Set Forth Below
2	Dark Horse Consulting Group, Inc., together with its subsidiaries Dark Horse Consulting Europe Limited and Dark Horse Consulting Middle East Limited	Statement of Work #22104 Clinical Hold Response Strategy Support	Clinical Operations and CT, CRO, sites, consultants	3/22/2022	on the second anniversary of the Consulting Agreement Effective Date or if later, upon the completion of the Services in accordance with any pending Statement of Work	As Set Forth Below
3	Dark Horse Consulting Group, Inc., together with its subsidiaries Dark Horse Consulting Europe Limited and Dark Horse Consulting Middle East Limited	Statement of Work #22118 Complete Hold Response Authorship & Quality Audit	Clinical Operations and CT, CRO, sites, consultants	4/13/2022	9/30/2022	As Set Forth Below
4	Dark Horse Consulting Group, Inc., together with its subsidiaries Dark Horse Consulting Europe Limited and Dark Horse Consulting Middle East Limited	AMENDMENT #1 TO SOW #22118	Clinical Operations and CT, CRO, sites, consultants	3/1/2023	9/30/2022	As Set Forth Below
5	Dark Horse Consulting Group, Inc., together with its subsidiaries Dark Horse Consulting Europe Limited and Dark Horse Consulting Middle East Limited	Statement of Work #22192 Ad Hoc CMC & Technical Support	Clinical Operations and CT, CRO, sites, consultants	5/26/2022	within 6 months from effective date	As Set Forth Below
6	Dark Horse Consulting Group, Inc., together with its subsidiaries Dark Horse Consulting Europe Limited, Dark Horse Consulting Middle East Limited and Dark Horse Consulting Asia Pte. Ltd.	Statement of Work #24125 Clinical Operations Support	Clinical Operations and CT, CRO, sites, consultants	3/27/2024	after three month from effective date	As Set Forth Below
7	Dark Horse Consulting Group, Inc., together with its subsidiaries Dark Horse Consulting Europe Limited and Dark Horse Consulting Middle East Limited	Statement of Work #24045 Regulatory & Nonclinical Support	Clinical Operations and CT, CRO, sites, consultants	2/12/2024	after 6 month from effective date	As Set Forth Below
8	Dark Horse Consulting Group, Inc., together with its subsidiaries Dark Horse Consulting Europe Limited and Dark Horse Consulting Middle East Limited	AMENDMENT #1 TO SOW #24045	Clinical Operations and CT, CRO, sites, consultants	3/25/2024	same as SOW #24045	As Set Forth Below
9	Dark Horse Consulting Group, Inc., together with its subsidiaries Dark Horse Consulting Europe Limited, Dark Horse Consulting Asia Pacific Pte. Ltd. And Dark Horse Consulting Middle East Limited	Amendment #1 to Consulting Agreement	Clinical Operations and CT, CRO, sites, consultants	3/17/2024	3/18/2026	As Set Forth Below
10	Dark Horse Consulting Group, Inc., together with its subsidiaries Dark Horse Consulting Europe Limited and Dark Horse Consulting Middle East Limited	Statement of Work #23113 Regulatory, Quality Assurance and GMP Readiness Support	Clinical Operations and CT, CRO, sites, consultants	5/18/2023	after 6 month from effective date	As Set Forth Below

Kironic Contracts (Clinical Operations and CT, CRO, sites, consultants)						
No.	Other Party	Agreement Subject	Category	Effective Date	Expiration Date	Proposed Cure
11	Dark Horse Consulting Group, Inc., together with its subsidiaries Dark Horse Consulting Europe Limited and Dark Horse Consulting Middle East Limited	Statement of Work #22212 Pre-IND Support	Clinical Operations and CT, CRO, sites, consultants	6/16/2022	on the second anniversary of the Consulting Agreement Effective Date or if later, upon the completion of the Services in accordance with any pending Statement of Work	As Set Forth Below
12	Dark Horse Consulting Group, Inc., together with its subsidiaries Dark Horse Consulting Europe Limited and Dark Horse Consulting Middle East Limited	AMENDMENT #2 TO SOW #24045	Clinical Operations and CT, CRO, sites, consultants	6/26/2024	same as SOW #24045	As Set Forth Below
13	Dark Horse Consulting Group, Inc., together with its subsidiaries Dark Horse Consulting Europe Limited and Dark Horse Consulting Middle East Limited	AMENDMENT #3 TO SOW #24045	Clinical Operations and CT, CRO, sites, consultants	8/15/2024	12/31/2024	\$55,622.50
14	JG BioConsult, LLC	MASTER SERVICES AND CONSULTING AGREEMENT	Clinical Operations and CT, CRO, sites, consultants	7/6/2023	7/6/2025	\$780.00
15	LABCORP CENTRAL LABORATORY SERVICES LP	LABORATORY SERVICES AGREEMENT Central Laboratory Services	Clinical Operations and CT, CRO, sites, consultants	5/22/2023	until completion of the Services unless earlier terminated	As Set Forth Below
16	LABCORP CENTRAL LABORATORY SERVICES LP	STATEMENT OF WORK	Clinical Operations and CT, CRO, sites, consultants	9/8/2023	End of Enrollment (all Regions completed) Sep 2025; Estimated Final Data Lock Date Dec 2027	\$10,945.38
17	Medidata Solutions, Inc.	Sales Order Number 4295918	Clinical Operations and CT, CRO, sites, consultants	10/9/2024	10/8/2025	\$3,760.84
18	AIXIAL US, Inc.	MASTER SERVICES AGREEMENT	Clinical Operations and CT, CRO, sites, consultants	10/18/2024	10/17/2029 unless terminated earlier	As Set Forth Below
19	AIXIAL US, Inc.	MASTER SERVICES AGREEMENT TAKS ORDER NO 1	Clinical Operations and CT, CRO, sites, consultants	1/7/2025	8/18/2026	\$81,943.97
20	SAFE HARBOR PHARMACOVIGILANCE, LLC	MASTER SERVICES AGREEMENT	Clinical Operations and CT, CRO, sites, consultants	10/23/2024	10/22/2029 unless terminated earlier	As Set Forth Below

Kironic Contracts (Clinical Operations and CT, CRO, sites, consultants)						
No.	Other Party	Agreement Subject	Category	Effective Date	Expiration Date	Proposed Cure
21	SAFE HARBOR PHARMACOVIGILANCE, LLC	STATEMENT OF WORK # 1	Clinical Operations and CT, CRO, sites, consultants	11/7/2024	until closeout of the study	\$13,494.17
22	Canopy Bioscience LLC	STATEMENT OF WORK	Clinical Operations and CT, CRO, sites, consultants	11/30/2023	11/30/2024 unless terminated earlier	\$4,272.42
23	Advarra, Inc	STUDY SPECIFIC INDEMNIFICATION AGREEMENT	Clinical Operations and CT, CRO, sites, consultants	4/17/2024	For DELTACEL-01 clinical trial	\$1,580.00

Kironic Contracts (Facilities)						
No.	Other Party	Agreement Subject	Category	Effective Date	Expiration Date	Proposed Cure
1	Miltenyi Biotech, Inc.	Quotation 7046569-00	Facilities	10/1/2024	9/30/2025	\$59,976.46

Kiromic Contracts (GMP)						
No.	Other Party	Agreement Subject	Category	Effective Date	Expiration Date	Proposed Cure
1	CRYOGENE	MSA	GMP	2/1/2022	2/1/2023	As Set Forth Below
2	CRYOGENE	2024 Quote for Storage and Services	GMP	2/13/2024	2/13/2025	As Set Forth Below
3	CRYOGENE	2024 Quote for Storage	GMP	7/15/2024	not specified	\$25,754.15
4	ALLCELLS	Clinical Supply Agreement	GMP	6/9/2023	until cancellation or termination	As Set Forth Below
5	ALLCELLS	Clinical Grade Fresh Leukopak Statement of Work	GMP	6/1/2023		As Set Forth Below
6	ALLCELLS	Quality Agreement	GMP	1/20/2022	same date as that the Master Supply Agreement terminates or expires	\$7,636.00
7	cryoport	Advanced Therapy Shipper Client Set-Up Form	GMP			\$32,287.18

Kiromic Contracts (IT)						
No.	Other Party	Agreement Subject	Category	EffectiveDate	Expiration Date	Proposed Cure
1	Cogent Communications, Inc	CUSTOMER ORDER FORMEthernet Point-to-Point and VPLS Services + Network Services Terms and Conditions	IT	12/3/2021	12/3/2024	\$3,005.16
2	EQUINIX	EQUINIX ORDER	IT	9/29/2021	10/28/2021	\$8,376.30
3	Rights Chain Ltd.	Consulting Agreement	IT	1/4/2020	until terminated	As Set Forth Below
4	Rights Chain Ltd.	Order # SP/2024/10/00041	IT	10/10/2024	7/1/2028	\$13,421.40

Kiromic Contracts (MS&T)						
No.	Other Party	Agreement Subject	Category	EffectiveDate	Expiration Date	Proposed Cure
1	Versiti, Inc.	ecimen Material Supply Agre	MS&T	5/15/2024	until terminated	\$5,115.00

SCHEDULE 4
ASSIGNED LEASES

Commercial lease with Cambridge Properties for multiple office suites located at 7707 Fannin Street, Houston, Texas, 77054.

SCHEDULE 5
ASSUMED EMPLOYEE RELATED OBLIGATIONS AND LIABILITIES

	First	Last	TITLE	Amount to be Paid*
1	A	A	QUALITY CONTROL ANALYST I, EM	\$4,615.38
2	K	A	CORPORATE PARALEGAL	\$4,000.00
3	A	D	QUALITY CONTROL ANALYST, ANALYTICAL	\$5,627.23
4	B	B	HEAD OF ASSAY DEVELOPMENT	\$10,207.15
5	M	B	CLINICAL TRIAL SPECIALIST	\$5,384.62
6	C	C	CELL THERAPY SPECIALIST LEAD	\$6,671.23
7	A	C	SHIPPING LEAD	\$7,000.00
8	C	C	FACILITIES ENGINEER	\$7,961.54
9	S	D	CHIEF MEDICAL OFFICER	\$28,076.92
10	A	D	INVENTORY SPECIALIST II	\$5,384.62
11	P	F	EXECUTIVE ASSISTANT	\$9,394.62
12	M	F	CELL THERAPY TECHNICIAN II	\$5,307.69
13	T	F	IT SUPPORT SPECIALIST	\$5,517.38
14	P	G	RESEARCH ASSOCIATE	\$5,384.00
15	C	G	HEAD OF QUALITY CONTROL	\$7,923.08
16	J	G	SUPPLY CHAIN SPECIALIST II	\$5,842.23
17	C	G	ASSOCIATE DIRECTOR OF QUALITY ASSURANCE	\$12,615.38
18	A	G	VP OF R&D	\$15,296.15
19	B	J	ASSOCIATE DIRECTOR OF QUALITY ASSURANCE	\$12,615.38
20	J	K	SR. DIR OF MSAT AND TECHNICAL OPERATIONS	\$14,103.08
21	P	K	SCIENTIST I	\$8,461.54
22	S	M	SR. DIR OF GMP OPERATIONS	\$14,240.00
23	N	N	QC MANAGER, MICROBIOLOGY	\$6,923.08
24	J	O	CELL THERAPY SPECIALIST II	\$5,852.23
25	L	P	SIR DIR OF STRATEGIC INNOVATION	\$12,538.46
26	J	P	MSAT SCIENTIST I	\$6,538.46
27	R	P	QC ANALYST, EM	\$5,867.31
28	T	S	CONTROLLER	\$14,657.69
29	L	S	QC ANALYST III	\$6,153.85
30	E	S	AP & PAYROLL SPECIALIST	\$5,878.92

*The amounts listed in this column reflect the gross amount to be paid. The amount actually received by each employee will reflect appropriate withholdings, and any other required payments, which amounts Buyer will calculate and remit to the appropriate parties.

	First	Last	TITLE	Amount to be Paid*
31	B	T	QUALITY ASSURANCE SPECIALIST I	\$5,911.92
32	L	T	QUALITY ASSURANCE SPECIALIST II	\$6,608.08
33	M	W	SR DIR OF CLINICAL OPERATIONS	\$15,384.62
34	A	W	SR. LAB MANAGER	\$7,446.15
35	A	W	PURCHASING COORDINATOR	\$3,939.20
36	R	Y	SCIENTIST II	\$8,715.38
				\$314,044.58

SCHEDULE 6
ASSUMED OBLIGATIONS OF VENDORS AND OTHER CREDITORS

Vendor	Total Open Balance
Vendor	
Advarra, Inc	\$1,580.00
Aixial US Inc	\$81,943.97
AllCells LLC	\$7,636.00
Automated Building Solutions, Inc.	\$1,599.94
BioLegend	\$1,257.82
BioLife Solutions, Inc.	\$10,455.09
BioReliance Corporation	\$20,888.80
Brightly Software, Inc.	\$6,349.48
Canopy Biosciences LLC	\$4,272.42
CenterPoint Energy (auto debit)	\$35.53
Centigrade Service	\$1,608.32
Cogent Communications, Inc. (01)	\$481.43
Cogent Communications, Inc. (02)	\$2,523.73
CPA Global Limited	\$2,053.21
Cryogene, Inc	\$25,754.15
Cryoport Systems, Inc	\$32,287.18
Dark Horse Consulting Group, Inc.	\$55,622.50
Equinix, Inc	\$8,376.30
Fisher Scientific	\$18,063.28
Heat Transfer Solutions, Inc	\$17,379.00
Histowiz, Inc.	\$98.00
JG BioConsult LLC	\$780.00
LabCorp	\$10,945.38
Longwood University	\$10,000.00
Medidata Solutions, Inc.	\$3,760.84
Mettler-Toledo Rainin, LLC	\$2,330.27
Microbiologics, Inc	\$2,078.35
Miltenyi Biotec Inc.	\$59,976.46
New England Biolabs, Inc.	\$397.28
Professional Janitorial Services of Houston, Inc	\$31,384.88
RAE Security Southwest, LLC	\$823.60
Rights Chain	\$13,421.40
Robbin Frnka	\$4,387.50
Safe Harbor Pharmacovigilance LLC	\$13,494.17
Saint-Gobain Performance Plastics Corp.	\$12,551.53
Thermo Fisher Scientific	\$807.59
Thompson Safety LLC	\$432.28
Uline	\$472.66
Versiti Inc	\$5,115.00
WCG Clinical, Inc	\$624.00
World Courier Inc	\$19.89
Total - Vendor	\$474,069.23